p. 9557−9565
2476-762X
Vol.15/No.22
p. 9567−9574
2476-762X
Vol.15/No.22
p. 9575−9578
2476-762X
Vol.15/No.22
p. 9579−9586
2476-762X
Vol.15/No.22
p. 9587−9592
2476-762X
Vol.15/No.22
p. 9593−9597
2476-762X
Vol.15/No.22
p. 9599−9602
2476-762X
Vol.15/No.22
p. 9603−9606
2476-762X
Vol.15/No.22
p. 9607−9610
2476-762X
Vol.15/No.22
p. 9611−9614
2476-762X
Vol.15/No.22
p. 9615−9619
2476-762X
Vol.15/No.22
p. 9621−9625
2476-762X
Vol.15/No.22
p. 9627−9630
2476-762X
Vol.15/No.22
p. 9631−9634
2476-762X
Vol.15/No.22
p. 9635−9641
2476-762X
Vol.15/No.22
p. 9643−9647
2476-762X
Vol.15/No.22
p. 9649−9654
2476-762X
Vol.15/No.22
p. 9655−9660
2476-762X
Vol.15/No.22
p. 9661−9666
2476-762X
Vol.15/No.22
p. 9667−9672
2476-762X
Vol.15/No.22
p. 9673−9678
2476-762X
Vol.15/No.22
p. 9679−9685
2476-762X
Vol.15/No.22
p. 9687−9692
2476-762X
Vol.15/No.22
C Polymorphism with Breast Cancer Risk: a Meta-analysis]]>
C polymorphism (rs5275) in the cyclooxygenase-2 (COX-2)gene and breast cancer (BC) risk are still inconclusive and ambiguous. The aim of this meta-analysis was tocomprehensively estimate the genetic risk of 8473T>C polymorphism in the COX-2 gene for BC. Materials andMethods: We searched PubMed, Web of Science, Medline, Chinese biomedical (CBM), Weipu, China nationalknowledge infrastructure (CNKI), and Wanfang databases, covering all publications (last search was updated onAug 17, 2014). Statistical analyses were performed using Revman 5.3 and STATA 10.0 software. Results: A totalof 6,720 cases and 9,794 controls in 12 studies were included in this study. The results indicated no significantassociations between the 8473T>C polymorphism of the COX-2 gene and BC risk for the CC+TC vs TT model(pooled odds ratio (OR)=0.97, 95% confidence interval (CI)=0.90-1.03, and p=0.29). On subgroup analysis, wealso found that subdivision on ethnicity among Caucasians, Asians and others also revealed no relationshipwith BC susceptibility. With the study design (CC+TC vs TT), no significant associations were found in eitherpopulation-based case-control studies (PCC), or hospital-based case-control studies (HCC). Conclusions: Thispresent meta-analysis suggests that the 8473T>C polymorphism in the COX-2 gene is not a conspicuous lowpenetrantrisk factor for developing BC.]]>
p. 9693−9698
2476-762X
Vol.15/No.22
p. 9699−9706
2476-762X
Vol.15/No.22
p. 9707−9711
2476-762X
Vol.15/No.22
p. 9713−9717
2476-762X
Vol.15/No.22
p. 9719−9723
2476-762X
Vol.15/No.22
p. 9725−9730
2476-762X
Vol.15/No.22
p. 9731−9737
2476-762X
Vol.15/No.22
p. 9739−9745
2476-762X
Vol.15/No.22
p. 9747−9751
2476-762X
Vol.15/No.22
p. 9753−9757
2476-762X
Vol.15/No.22
p. 9759−9761
2476-762X
Vol.15/No.22
p. 9763−9766
2476-762X
Vol.15/No.22
p. 9767−9771
2476-762X
Vol.15/No.22
p. 9773−9779
2476-762X
Vol.15/No.22
p. 9781−9784
2476-762X
Vol.15/No.22
p. 9785−9790
2476-762X
Vol.15/No.22
p. 9791−9795
2476-762X
Vol.15/No.22
p. 9797−9800
2476-762X
Vol.15/No.22
50 years (39.6% vs 16.6%; PR 3.29; 95% CI 2.59-4.12; p<0.001). Neoplastic lesions was found in 257 (16.1%),comprising 180 (11.3%) adenomas, 10 (0.6%) in situ carcinomas, and 67 (4.2%) carcinomas. Conclusions: Polypsor masses were found in 30% of colonoscopy patients and malignancies in 16.1%. These figures do not representthe nation-wide demographic status of colorectal cancer, but may reflect a potentially increasing major healthproblem with colorectal cancer in Indonesia.]]>
p. 9801−9804
2476-762X
Vol.15/No.22
p. 9805−9812
2476-762X
Vol.15/No.22
p. 9813−9815
2476-762X
Vol.15/No.22
p. 9817−9822
2476-762X
Vol.15/No.22
p. 9823−9829
2476-762X
Vol.15/No.22
p. 9831−9834
2476-762X
Vol.15/No.22
p. 9835−9839
2476-762X
Vol.15/No.22
p. 9841−9846
2476-762X
Vol.15/No.22
p. 9847−9851
2476-762X
Vol.15/No.22
p. 9853−9857
2476-762X
Vol.15/No.22
p. 9859−9863
2476-762X
Vol.15/No.22
p. 9865−9869
2476-762X
Vol.15/No.22
p. 9871−9873
2476-762X
Vol.15/No.22
p. 9875−9877
2476-762X
Vol.15/No.22
p. 9879−9884
2476-762X
Vol.15/No.22
p. 9885−9889
2476-762X
Vol.15/No.22
p. 9891−9898
2476-762X
Vol.15/No.22
p. 9899−9903
2476-762X
Vol.15/No.22
p. 9905−9908
2476-762X
Vol.15/No.22
p. 9909−9913
2476-762X
Vol.15/No.22
p. 9915−9919
2476-762X
Vol.15/No.22
p. 9921−9926
2476-762X
Vol.15/No.22
p. 9927−9931
2476-762X
Vol.15/No.22
p. 9933−9937
2476-762X
Vol.15/No.22
p. 9939−9943
2476-762X
Vol.15/No.22
p. 9945−9948
2476-762X
Vol.15/No.22
p. 9949−9953
2476-762X
Vol.15/No.22
p. 9955−9960
2476-762X
Vol.15/No.22
p. 9961−9966
2476-762X
Vol.15/No.22
p. 9967−9972
2476-762X
Vol.15/No.22
0.05). For g.G1790A genotypes, all patients and controls had only GG genotype. Conclusions:The three HIF-1α polymorphisms (g.C111A, g.C1772T and g.G1790A) are not associated with breast cancerrisk in North-West Indian patients.]]>
p. 9973−9978
2476-762X
Vol.15/No.22
p. 9979−9983
2476-762X
Vol.15/No.22
p. 9985−9996
2476-762X
Vol.15/No.22
p. 9997−10001
2476-762X
Vol.15/No.22
p. 10003−10008
2476-762X
Vol.15/No.22
p. 10009−10013
2476-762X
Vol.15/No.22
p. 10015−10020
2476-762X
Vol.15/No.22
p. 10021−10025
2476-762X
Vol.15/No.22
p. 10027−10031
2476-762X
Vol.15/No.22
p. 10033−10038
2476-762X
Vol.15/No.22
p. 10039−10043
2476-762X
Vol.15/No.22